Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- NVDQ -17.3%, (sees Q4 rev below consensus; sees FY17 rev below consensus), SVU -8.1%, SIG -4.6%, BWA -1.9%, LMNR -1.6%
M&A news:
- ADM -5.6% (to acquire Crosswind Industries; terms not disclosed)
Select pharma related names showing weakness:
- BMY -3.6%, AZN -1.6%, SHPG -1.1%
Other news:
- SGNL -12.8% (pulling back following recent strength)
- ETRM -11.2% (pulling back following recent strength)
- GNVC -7.4% (pulling back following recent strength)
- PTN -5.3% (Palatin Technologies to hold call following closing of licensing agreement with AMAG Pharmaceuticals for North American rights to Rekynda)
- PFGC -5% (prices 10 mln common stock offering by certain of its stockholders, including affiliates of The Blackstone Group (BX) at $22.85/share )
- BRG -4.7% (commenced a public offering of 4,000,000 shares of its Class A common stock)
- TERP -4.5% (Brookfield Asset Management affirms 12.12% active stake, discloses the submission of alternative proposals to the company's advisors with respect to a potential transaction involving the company and/or TerraForm Global)
- PE -2.9% (announces Midland Basin and Delaware Basin acquisitions and introduces 2017 capital program and operating guidance; expects ~60% annual production growth in 2017; commenced an underwritten public offering of 20,000,000 shares of Class A common stock), .
Analyst comments:
- HIMX -2.5% (downgraded to Neutral from Buy at ROTH Capital)
- WUBA -1.6% (initiated with a Underperform at Bernstein)
- JD -1% (initiated with an Underperform at Bernstein )
- C -0.8% (downgraded to Sell at UBS)
- BIDU -0.7% (initiated with a Underperform at Bernstein)